A phase2 study of Rituximab+THP-COP(R-THP-COP) in elderly subjects with untreated, advanced, CD20-positive, indolent B-cell Non-Hodgkin's lymphoma

A phase2 study of Rituximab+THP-COP(R-THP-COP) in elderly subjects with untreated, advanced, CD20-positive, indolent B-cell Non-Hodgkin's lymphoma - THP2

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002287

Enrollment

Registered

2009-08-03

Start date

2005-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

indolent B-cell lymphoma

Interventions

Rituximab,Cyclophosphamide,Pirarubicin,Vincristine,Prednisolone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Subjects with diagnosis of CD20-positive,indolent B-cell Non-Hodgkin's lymphoma 2.Age70-79years 3.Eastern Cooperative Oncology Group(ECOG) performance status 0-2 4.

Exclusion criteria

Exclusion criteria: 1.Central nervous system(CNS) NHL 2.Current or chronic hepatitis B or C infection;known seropositiviry for human immunodeficiency virus(HIV). 3.Any evidence of serious active infection 4.Unstable or severe uncontrolled medical condition or any important medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the risk associated with the subject's participation in the study.

Design outcomes

Primary

Measure	Time frame
Complete response rate,safty	—

Secondary

Measure	Time frame
overall response rate,progression-free survival,overall survival,safty	—

Countries

Japan

Contacts

Public ContactKazunori Ohnishi

Hamamatsu University school of Medicine Oncology center

053-435-2267

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

A phase2 study of Rituximab+THP-COP(R-THP-COP) in elderly subjects with untreated, advanced, CD20-positive, indolent B-cell Non-Hodgkin&#39;s lymphoma